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Thrombotic occlusion of a mechanical valve prosthesiscan be life threatening and requires urgent evaluationand treatment. Traditionally, the treatment for mechan-ical valve thrombosis has been urgent reoperation with
attempted declotting of the valve or valve rereplacement. Unfor-
tunately, this is associated with a high mortality, and efforts have
been made to pursue nonoperative treatment with thrombolytics.
There are many reports of the successful use of thrombolytics in
adults, but very little data are reported in the pediatric population.
We review the literature, report 2 cases of successful treatment of
mechanical mitral valve thrombotic occlusion with thrombolytic
therapy in children, and summarize the major reports of thrombo-
lytic use for prosthetic valve occlusion in the pediatric population.
Clinical Summary
PATIENT 1. The patient was born with a complete atrioventricular
canal and coarctation in June 1999. Shortly after birth, she under-
went coarctation repair along with palliative pulmonary artery
banding. She subsequently had a definitive repair of her atrioven-
tricular canal. This was complicated by mitral regurgitation and
heart block requiring pacemaker insertion. Her mitral regurgitation
progressively worsened, and she required mitral valve replacement
in 2002 with a 17-mm St Jude Medical (St Jude Medical, Inc, St
Paul, Minn) mechanical prosthesis. At this time, her family moved
to Atlanta, and she was referred to Egleston Hospital, Children’s
Healthcare of Atlanta, for further care. In January 2003, a routine
echocardiogram and subsequent cardiac catheterization revealed
mitral valve stenosis with a mean gradient of 11 mm Hg across the
valve, increased pulmonary artery pressures, and calcification with
posterior leaflet fixation of her mechanical prosthesis. She was
taken to the operating room for rereplacement of her mitral valve
with a 21-mm St Jude Medical mechanical prosthesis. Over the
next 3 months, she required multiple operative interventions for
pacemaker revisions-replacements, with each requiring interrup-
tion of her anticoagulant regimen. During one of her admissions in
March, an echocardiogram revealed a worsening gradient of 10
mm Hg across the mitral valve compared with that seen in previ-
ous studies. Valve fluoroscopy demonstrated an anterior leaflet
with one half the normal motion and a fixed posterior leaflet. She
was started on tissue plasminogen activator (TPA) infusion at 0.1
mg · kg1 · h1, and this was gradually increased to 0.4 mg · kg1
· h1 over 24 hours. Repeat valve fluoroscopy was unchanged at
24 hours but showed normal function, with full leaflet excursion at
36 hours. At this point, her TPA infusion was discontinued. She
was started on a heparin drip and warfarin sodium (Coumadin).
Her heparin was discontinued when her warfarin level was thera-
peutic. She was discharged from the hospital without a repeat
operation for valve thrombosis. Echocardiography in May con-
firmed normal valve function without a significant gradient.
PATIENT 2. The patient was born with an unbalanced atrioven-
tricular canal, multilevel pulmonary stenosis, and a borderline but
adequate mitral valve annulus in June 2002. In March 2003, she
underwent a 2-ventricle repair of her atrioventricular canal with
pulmonary valve commisurotomy and pulmonary artery patch
angioplasty. Her initial postoperative course was unremarkable,
but she returned in May with increased work of breathing and
lethargy. An echocardiogram at that time revealed an increased
mitral valve velocity with a peak gradient of 29 mm Hg and a
mean gradient of 17 mm Hg across the valve. She was taken back
to the operating room, where she underwent mitral valve replace-
ment with a 17-mm St Jude Medical mechanical prosthesis. Sev-
eral days after the operation, her postoperative course was com-
plicated by bleeding after removal of a right atrial intracardiac line.
Control of the bleeding required interruption of her anticoagulant
regimen, exploration, and suture closure of the right atrium. De-
spite restarting her anticoagulation after this episode, a routine
echocardiogram a week later revealed moderate prosthetic mitral
valve stenosis. Only one leaflet was moving, and the gradient
across the valve had increased from that seen on the immediate
postoperative echocardiogram. Valve fluoroscopy confirmed poor
anterior leaflet mobility and an immobile posterior leaflet. She was
given a streptokinase bolus of 2000 U/kg and started on a strep-
tokinase infusion of 2000 U · kg1 · h1, but the results of repeat
valve fluoroscopy 24 hours later was unchanged. Her streptokinase
was discontinued, and she was started on a TPA infusion at 0.05
mg · kg1 · h1, which was gradually increased to 0.5 mg · kg1
· h1 over 24 hours. Valve fluoroscopy 24 hours later showed no
resolution. She was subsequently transported to the operating room
for mitral valve thrombectomy-rereplacement; however, her pre-
operative transesophageal echocardiogram demonstrated normal
valve function with a normal gradient across the valve. Both
leaflets were freely mobile and without evidence of thrombus. She
was returned to the cardiac intensive care unit, where her TPA was
discontinued. She was started on a heparin drip and warfarin. Her
heparin was discontinued when her warfarin level was therapeutic.
She was discharged from the hospital without a repeat operation
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for valve thrombosis, and an echocardiogram 1 month later con-
firmed normal valve function without significant gradient.
Discussion
Because the options for mitral valve replacement are limited in
young children, valve repair is indicated if at all possible. With
mild or moderate symptoms, surgical intervention is delayed so
that if valve replacement is required, an adult-sized prosthesis can
be used.1 Because bioprosthetic valves degenerate rapidly in in-
fants and children, mechanical prostheses are typically used for
these patients so long as there are no contraindications to antico-
agulation.
Unfortunately, there are many complications associated with
mechanical valve replacement. These include thromboembolism,
acute thrombotic occlusion, complications of long-term anticoag-
ulation, prosthetic valve endocarditis, periprosthetic leakage,
chronic hemolysis, and reoperation. The incidence of acute throm-
botic occlusion of a mechanical replacement device is 0.03% to
8% per patient-year.2-5 This complication occurs primarily in
patients with suboptimal anticoagulant therapy, which usually
results when therapy is stopped or interrupted for a surgical pro-
cedure. The only other risk factor that has been identified is female
sex.1
The presentation of these patients ranges from asymptomatic
thrombotic occlusion detected by means of routine echocardiog-
raphy to cardiogenic shock. The most common symptoms include
those of pulmonary venous hypertension: dyspnea, orthopnea, and
paroxysmal nocturnal dyspnea. Other signs and symptoms include
a decrease in the intensity of the prosthetic heart valve sounds,
systemic thromboembolism, or the signs and symptoms of con-
gestive heart failure. Cardiac examination reveals a prominent
apical middiastolic murmur of mitral stenosis. Electrocardiography
shows a tracing consistent with left atrial hypertrophy, and chest
radiography shows left atrial enlargement.
Confirmation is usually achieved with a fluoroscopic valve
examination or echocardiography. These modalities play comple-
mentary roles, with fluoroscopy providing information solely
about restriction of leaflet motion and echocardiography providing
hemodynamic information about pressure gradients and valve ar-
eas.4 Cardiac catheterization is rarely indicated for confirmation of
the diagnosis.1
Thrombosis of a prosthetic valve can be a catastrophic event.
Traditional therapy for this condition is emergency thrombectomy,
with valve rereplacement as needed. When patients are taken to the
operating room, valve thrombectomy is attempted first. However,
there are times when thrombectomy is not feasible and valve
rereplacement is required. Most commonly, this results from or-
ganization and fibrosis of the thrombotic material or when the
thrombus is located on the ventricular side of the valve and cannot
be extracted without removing the prosthesis. Risks of operation
include all of the risks of an initial valve operation, along with the
risk of reoperation. Reoperation mortality is dependent on age,
function of the heart, whether the procedure is performed on an
elective or emergency basis, and whether the prosthesis is infected.
Reoperation for a failed valve has a mortality of 5% to 20%,4,6,7
with mortality statistics becoming increasingly worse with each
subsequent reoperation.
Several factors have prompted the nonoperative treatment of
valve thrombosis with thombolytic therapy. First, the morbidity
and mortality of valve reoperation is significant. Second, the risk
of acute thrombotic occlusion is not linear. The likelihood of acute
thrombotic occlusion has a peak early after the operation and then
decreases to a low level several years after the operation. Finally,
the majority of patients do not have a problem intrinsic to the
prosthetic valve, but the complication has developed from inade-
quate anticoagulation. Thrombolysis provides an opportunity to
treat the valve thrombosis, avoid surgical intervention and save the
prosthetic valve, and achieve a good long-term result.
Recently, thrombolytic agents, such as TPA, streptokinase, and
urokinase, have allowed nonoperative treatment of some prosthetic
valve thromboses. Patient selection is a crucial factor in successful
nonoperative treatment. Patients with organized fibrosis are less
likely to achieve success with thrombolytic therapy and benefit
from primary surgical intervention. Also, thrombolytics should
only be used in patients without signs of cardiogenic shock.
Patients with contraindications to thrombolytic therapy or those in
low-output states should undergo emergency operations.
Results, primarily from adult series, appear to be very promis-
ing.3-10 The general efficacy is approximately 70% to 75%. There
is increased efficacy of thrombolytics for occlusion of prosthetic
valves in the aortic position compared with in the mitral position.
Most studies used single-agent regimens, and there was no differ-
ence in efficacy between TPA and streptokinase. Some studies
showed even higher success rates with combined agents in those
patients in whom single-agent therapy failed. There was no dif-
ference in the efficacy according to valve type or for episodes of
recurrent thrombosis. Complications occurred in approximately
25% of patients. These included major bleeding episodes, systemic
thromboembolism, failure resulting in reoperation, or death. Mor-
tality was 0% to 10%.
Thrombolytic therapy is also emerging as a suitable alternative
to reoperation in children with prosthetic valve occlusion. There
are only limited data in the pediatric population because of the
infrequent nature of this problem. Table 16,7,11-16 summarizes the
major reports of thrombolytic use for prosthetic valve occlusion in
the pediatric population. The combination of our 2 patients with
those from 9 other studies total 26 patients less than 18 years of
age. These patients had a total of 32 occurrences of prosthetic
valve thrombosis, of which 31 were treated with thombolytics. The
overall success rate of thrombolytic treatment for valve thrombosis
was 87% (27/31).
The state of anticoagulation was known at the time of valve
thrombosis in 24 occurrences. Of these, 75% (18/24) of occur-
rences involved either interruption of the anticoagulation regimen
for surgical intervention, cessation of the regimen because of
noncompliance, or inadequate levels of anticoagulation. According
to valve type, 20 occurrences involved a St Jude Medical valve
with a success rate of 80% (16/20), 8 occurrences involved a
Carbomedics (Sulzer Carbomedics, Inc, Austin, Tex) valve with a
success rate of 75% (6/8), and 3 occurrences involved other valves
or were unknown. According to thrombolytic regimen, 17 occur-
rences were treated with TPA only with a success rate of 88%
(15/17), 10 occurrences were treated with streptokinase only with
a success rate of 90% (9/10), and 4 occurrences were treated with
another agent or a combined regimen. Interestingly, our patient
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TABLE 1. Summary of major reports of thrombolytics in prosthetic valve occlusion in children less than 18 years of age
Study
(no. of patients <18 y) Age
No. of
occurrences
Therapeutic
anticoagulation
(warfarin)
Valve position-
type
Thrombolytic
agent
Outcome (success, failure,
rethrombosis, operation, death)
Bolz and associates,
200011 (1)
17 y 1 No Tr-SJM TPA Success
(Current report, 2003) (2) 3 y 1 No Mi-SJM TPA Success
1 y 1 No Mi-SJM SK/TPA Success
Fyfe and associates,
199112 (2)
8 y 2 No
Yes
Tr-SJM SK Success with subsequent
rethrombosis; subsequent
valve replacement without
attempted rethrombolysis
11 y 1 No Pu-SJM SK Success
Joyce and associates,
198313 (1)
16 mo 1 No Tr-SJM UK Success
Koska and associates,
199214 (1)
22 mo 1 Yes Tr-SJM TPA Success
Kothari and Wasim,
199315 (1)
5 y 1 Yes Ao-Bjo¨rk-Shiley SK Success
Munclinger and
associates, 19986 (5)
13 y
16 y
1
1
No
Yes
Mi-SJM
Mi-SJM
TPA
TPA
Success
Success
11 y 1 No Ao, Mi-SJM TPA Success, death several weeks
later with nontherapeutic
anticoagulation
16 y 2 Yes Mi-SJM TPA Success with subsequent
rethrombosis
Yes TPA Repeat success with
rethrombolysis
13 y 1 No Mi-SJM TPA Failure leading to valve
replacement
Reddy and associates,
19947 (8)
15 y
17 y
1
1
No
No
Mi-Carbomedics
Mi-Carbomedics
SK
SK/UK
Success
Failure in patient who arrived
moribund in cardiogenic shock
17 y 1 No Mi-Carbomedics SK Success complicated by
retroperitoneal bleed
13 y 1 No Mi-Carbomedics SK Success
16 y 2 No Mi-Carbomedics SK Success with subsequent
rethrombosis
No SK Repeat success with
rethrombolysis
15 y 1 No Mi-Carbomedics SK Failure in patient who arrived
moribund in cardiogenic shock
14 y 1 No Mi-Carbomedics SK Success
18 y 1 No Mi-SJM UK Success
Ries and associates,
199416 (2)
3 y
12 y
1
1
Mi
Tr
TPA
TPA
Success
Success
Serpi and associates,
200117 (3)
4 mo
10 mo
1
4
A-V-SJM
A-V-SJM
TPA
TPA
Success
Success with subsequent
rethrombolysis
TPA Repeat success with
rethrombolysis
TPA Repeat success with
rethrombolysis
TPA Failure leading to valve
replacement
18 mo 1 A-V-SJM TPA Success
Tr, Tricuspid; TPA, tissue plasminogen activator; SJM, St Jude Medical; Mi, mitral; SK, streptokinase; Pu, pulmonary; Ao, aortic; A-V atrioventricular; UK,
urokinase.
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was converted from streptokinase to TPA after 24 hours, and
subsequently her thrombosis resolved. Overall, there did not ap-
pear to be a difference in the results according to the valve type or
thrombolytic regimen. The complications of thrombolytic therapy
in this population included failure to alleviate the obstruction,
initial success with subsequent rethrombosis, hemorrhage, need for
reoperation, and death. There were only 4 (13%) occurrences of
valve thrombosis in which thombolytic therapy failed. There were
3 failures at the initial occurrence, resulting in 2 deaths and 1
reoperation, and 1 failure at a subsequent occurrence, after which
the patient underwent reoperation. There were 6 episodes of initial
successful thrombolysis, followed by subsequent rethrombosis.
One patient was taken to the operating room for valve rereplace-
ment without a repeat attempt at thrombolysis. Of the 5 patients
who were treated with repeat thromobolytics, the success rate was
80% (4/5), with the patient in whom there was a failure also
proceeding to the operating room. There were no embolic compli-
cations reported and only one hemorrhagic complication consist-
ing of a retroperitoneal bleed. Of the total number of attempts at
thrombolytic therapy, only 10% (3/31) resulted in death. One death
occurred several weeks after successful thrombolysis in a patient
found to be inadequately anticoagulated. It was not known whether
the death was due to rethrombosis of the valve. The other 2 deaths
occurred in patients who arrived to the hospital moribund in
cardiogenic shock, where thrombolytics were used as a last effort
as salvage therapy.
Although it seems quite promising, the literature is difficult to
interpret. Overall, there are relatively few patients with prosthetic
valve thrombosis. Some of these patients are taken directly to the
operating room without attempted thrombolysis because of con-
traindications to thrombolytic therapy, refusal of thrombolytic
therapy, or physician preference. On the other hand, some of these
patients might be deemed too sick for surgical intervention and are
offered thrombolytic therapy as a last-resort treatment option.
Also, unsuccessful attempts at thrombolysis followed by an oper-
ation are not necessarily reported.
Conclusion
The results of thrombolytic therapy for prosthetic valve thrombosis
are encouraging. Given the significant risks associated with emer-
gency valve thrombectomy-rereplacement, fibrinolytic therapy
might prove to be a safer alternative for this difficult problem in
the pediatric population.
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